Kyushu University · 의학
마사히로 아야노 교수의 연구실은 자가면역질환, 특히 시스템릭 루푸스 에리테마토데이소스(SLE)와 시스템스클로로시스(SSc)의 면역학적 기전을 규명하는 데 초점을 맞추고 있습니다. 보조성 면역세포인 기억세포 CD8(+) T세포와 보조성 보조세포인 CD226 발현 B세포의 역할을 분석하며, 보다 정밀한 생물학적 마커와 치료 전략 개발을 추구하고 있습니다. 특히 보조성 보조세포 활성화 및 보조성 보조성 조절 메커니즘을 중심으로 혁신적인 치료 전략 개발을 위한 기초 연구를 진행하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products
Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular damage and fibrosis of the skin and internal organs. Because activated and oligoclonally expanded CD8(+) T cells can be detected in peripheral blood and lungs of SSc patients, effector memory CD8(+) T cells may play a critical role for organ involvement in SSc; however, the pathogenic functions of effector memory CD8(+) T cells remain incompletely understood. In this study, we performed DNA microarray analysis of the sor
CD34-selected auto-HSCT may produce favourable effects on improvement of skin sclerosis and pulmonary function compared with unmanipulated auto-HSCT. Use of CD34-selected auto-HSCT with high-dose cyclophosphamide monotherapy as a conditioning regimen may offer an excellent benefit-to-risk balance.
Increased proportion of CD226<sup>+</sup> B cells was associated with disease activity and prognosis of SLE. CD226<sup>+</sup> B cells may be a useful biomarker for the management of SLE.
There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.
MZR is as effective as MMF in controlling SLE activity. The adverse events of MZR, whose profile differs from MMF, are comparable to or less than those of MMF. MZR may be a valuable option as an immunosuppressive agent for SLE, as well as MMF.
The efficacy and safety of an add-on treatment with HCQ are similar to those with TAC. Patients with persistently active SLE can benefit from HCQ in efforts to achieve at least low disease activity.
Biological agents were used preferentially, and the therapeutic agents were appropriately effective and mostly achieved the purpose of agent initiation.
